EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Evidence-Based Medicine 2006;11:50; doi:10.1136/ebm.11.2.50
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernandez, A. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernandez, A. F
Topic Collections
Right arrowRelevant Article

Therapeutics

A centralised telephone intervention reduced combined all cause mortality or admission for worsening HF in chronic heart failure

GESICA Investigators. Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ 2005;331:425.[Abstract/Free Full Text]

Q In patients with chronic heart failure (HF), does a centralised telephone intervention by nurses reduce combined all cause mortality or admission for worsening heart failure?

Clinical impact ratings GP/FP/Primary care ******{star} Internal medicine ******{star} Cardiology ******{star}

Key Words: ambulatory care • cardiac output (low) • hotlines

The first 150 words of the full text of this article appear below.

METHODS
Formula Design: randomised controlled trial.

Formula Allocation: concealed.*

Formula Blinding: blinded (outcome adjudicators {and data analysts}{dagger}).*

Formula Follow up period: mean 16 months (range 7–27 mo).

Formula Setting: 51 centres (public and private hospitals and ambulatory settings) in Argentina.

Formula Patients: 1518 outpatients (mean age 65 y, 71% men) who were >=18 years of age; had stable HF diagnosed >=3 months previously, with no admissions in the past 2 months; and had optimal drug treatment that was not modified for >=2 months before the trial. Exclusion criteria included need for >1 medical visit per month; HF related to hypertrophic cardiomyopathy, significant valvular lesion, pericarditis or pericardial tamponade, primary pulmonary hypertension or cor pulmonale, or congenital cardiac malformations; reversible cardiomyopathy; recent (<=3 mo) myocardial infarction or unstable angina; recent cardiac surgery/angioplasty; planned cardiac surgery or heart transplantation; symptomatic sustained ventricular tachycardia or recent history of ventricular fibrillation; regular IV pulse therapy; recent stroke; symptomatic sick . . . [Full text of this article]

Adrian F Hernandez, MD

Duke University, Durham, North Carolina, USA


Relevant Article

Glossary
Evid. Based Med. 2006 11: 63a. (in Glossary) [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.